GLPwatch
Papers (10588)
Page 164 of 177, ranked by citation count.
- Clinical Characteristics of Users of Weight Loss Drugs: Population-Based Case-Control Study.
- Effect of dulaglutide and long-acting insulin combination therapy in patients with type 2 diabetes: a retrospective observational study.
- Tirzepatide as Adjunct to Insulin in Adults With Type 1 Diabetes and Overweight or Obesity: A Systematic Review of Randomized and Real-World Evidence.
- Response to "Liraglutide Effectiveness: Is There a Real-World Clinical Benefit?"
- Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process.
- [Treatment of type 2 diabetes mellitus with GLP-1 agonists].
- DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Bronchopulmonary dysplasia induced by hyperoxia attenuated by A GLP-1 analog, Liraglutide, by regulating the ACE-2/Ang(1-7)/Mas receptor pathway.
- Severe Adverse Effects of Tirzepatide Overdose Requiring Intensive Care Unit Admission and Complex Rehabilitation.
- Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review.
- Endometrial Transcriptome Changes following Short-Term Liraglutide Treatment in Infertile Women with Polycystic Ovarian Syndrome and Obesity.
- Efficacy of semaglutide in IgA nephropathy with obesity: a case report.
- Therapeutic efficacy, biomarker signatures, and translatability of semaglutide in the liver biopsy-confirmed GAN DIO-MASH mouse model.
- Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.
- Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.
- Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman.
- Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management.
- The Effect of Liraglutide on the Hypolipidemic, Anti-Inflammatory, and Antioxidant Properties of Atorvastatin Mediated via the Nrf2/HO-1 Signaling Pathway: In Vivo and In Silico Validation.
- Patients after acute myocardial infarction: potential of semaglutide in prognosis for reducing events and mortality.
- Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials.
- The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity.
- Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions.
- [New outcome studies with injectable semaglutide in different at risk populations].
- Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population-Based Cohort Study.
- Comment on: "Relative Effectiveness and Safety of the GLP-1 Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics" [Letter].
- Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.
- Glucagonlike peptide 1 analogs in diabetes care.
- [Possibilities of therapy GLP1 RA for diabetics with nephropathy].
- Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy.
- Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine.
- Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.
- Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review.
- Is liraglutide the solution for weight loss in women with polycystic ovarian syndrome?
- Comparative Efficacy of Tirzepatide vs Semaglutide on Liver and Cardiovascular Related Outcomes in Patients with MASLD/MASH, Obesity, and Type 2 Diabetes Mellitus: A Real-World Cohort Study.
- After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.
- GLP-1 and dual GIP/GLP-1 agonists in obese patients with HFpEF: a systematic review and meta-analysis of RCTs.
- Clinical and metabolic profile of adults with obesity attending lifestyle medicine clinics.
- GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
- Longacting exenatide in diabetes: DURATION-3.
- Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study.
- London buses: A cardiovascular outcome trial equivalent?
- Oral semaglutide (Wegovy) for weight loss.
- Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
- Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review.
- Comparative Effects of Antidiabetic Drugs on Body Composition: A Systematic Review and Network Meta-Analysis.
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
- Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.
- Improving sensitivity and drug tolerance of assays for neutralizing anti-drug antibodies to semaglutide and native GLP-1.
- Carnitine Deficiency Caused by Salcaprozic Acid Sodium Contained in Oral Semaglutide in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency.
- Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
- Evaluating the managed care implications of longer-acting basal insulin analog therapies.
- Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.
- [Glucagon-like peptide-1: a cardiological perspective].
- Medical Treatments for Obesity: What Does the Future Have in Store?
- Recurrent bilateral brachial plexus neuritis following rapid semaglutide-induced weight loss: a case report.
- Glucagon-like peptide-1 receptor agonists and rotator cuff disease: a scoping review.
- [GLP1 receptor agonist drug treatments and adult obesity].
- In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
- Roflumilast Enhances Liraglutide's Atrial Natriuretic Peptide-Dependent Suppression of Adrenal Aldosterone Secretion.